• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Cell . B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV

tetano

Editor, Senior Moderator
Cell


. 2021 Apr 24;S0092-8674(21)00535-3.
doi: 10.1016/j.cell.2021.04.032. Online ahead of print.
B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV


Johannes F Scheid[SUP] 1 [/SUP], Christopher O Barnes[SUP] 2 [/SUP], Basak Eraslan[SUP] 3 [/SUP], Andrew Hudak[SUP] 3 [/SUP], Jennifer R Keeffe[SUP] 2 [/SUP], Lisa A Cosimi[SUP] 4 [/SUP], Eric M Brown[SUP] 5 [/SUP], Frauke Muecksch[SUP] 6 [/SUP], Yiska Weisblum[SUP] 6 [/SUP], Shuting Zhang[SUP] 3 [/SUP], Toni Delorey[SUP] 7 [/SUP], Ann E Woolley[SUP] 4 [/SUP], Fadi Ghantous[SUP] 8 [/SUP], Sung-Moo Park[SUP] 3 [/SUP], Devan Phillips[SUP] 7 [/SUP], Betsabeh Tusi[SUP] 3 [/SUP], Kathryn E Huey-Tubman[SUP] 2 [/SUP], Alexander A Cohen[SUP] 2 [/SUP], Priyanthi N P Gnanapragasam[SUP] 2 [/SUP], Kara Rzasa[SUP] 3 [/SUP], Theodora Hatziioanno[SUP] 6 [/SUP], Michael A Durney[SUP] 3 [/SUP], Xiebin Gu[SUP] 3 [/SUP], Takuya Tada[SUP] 9 [/SUP], Nathaniel R Landau[SUP] 9 [/SUP], Anthony P West Jr[SUP] 2 [/SUP], Orit Rozenblatt-Rosen[SUP] 7 [/SUP], Michael S Seaman[SUP] 8 [/SUP], Lindsey R Baden[SUP] 4 [/SUP], Daniel B Graham[SUP] 5 [/SUP], Jacques Deguine[SUP] 3 [/SUP], Paul D Bieniasz[SUP] 10 [/SUP], Aviv Regev[SUP] 11 [/SUP], Deborah Hung[SUP] 12 [/SUP], Pamela J Bjorkman[SUP] 13 [/SUP], Ramnik J Xavier[SUP] 14 [/SUP]



Affiliations

Abstract

Monoclonal antibodies (mAbs) are a focus in vaccine and therapeutic design to counteract severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants. Here, we combined B cell sorting with single-cell VDJ and RNA sequencing (RNA-seq) and mAb structures to characterize B cell responses against SARS-CoV-2. We show that the SARS-CoV-2-specific B cell repertoire consists of transcriptionally distinct B cell populations with cells producing potently neutralizing antibodies (nAbs) localized in two clusters that resemble memory and activated B cells. Cryo-electron microscopy structures of selected nAbs from these two clusters complexed with SARS-CoV-2 spike trimers show recognition of various receptor-binding domain (RBD) epitopes. One of these mAbs, BG10-19, locks the spike trimer in a closed conformation to potently neutralize SARS-CoV-2, the recently arising mutants B.1.1.7 and B.1.351, and SARS-CoV and cross-reacts with heterologous RBDs. Together, our results characterize transcriptional differences among SARS-CoV-2-specific B cells and uncover cross-neutralizing Ab targets that will inform immunogen and therapeutic design against coronaviruses.

Keywords: COVID-19; SARS-CoV cross-neutralization; cryo-electron microscopy; disordered CDRH3; memory B cells; monoclonal antibodies; single B cell genomics.
 
Back
Top Bottom